Live Breaking News & Updates on Endocrine Therapies

Stay updated with breaking news from Endocrine therapies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

The Role of Elacestrant in Breast Cancer

Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile. ....

Erical Mayer , Breast Cancer , Hr Breast Cancer , Hr Positive Breast Cancer , Breast Cancer Treatment , Esr1 Mutations , Endocrine Therapies , Emerald Study , Emerald Trial , Pi3k Mutations ,

Evolution of Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

Experts discuss evolving strategies in ER+/HER2- metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes. ....

Breast Cancer , Endocrine Therapies , Oral Serd , Metastatic Breast Cancer , Therapeutic Advances , Panel Discussion , Her Positive , Her2 Negative , Selective Estrogen Receptor Degrader , Endocrine Therapy , Targeted Therapy , Treatment Developments , Medical Oncology , Breast Oncology ,

GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent. | May 24, 2023 ....

University Of Washington , United States , Hannahm Linden , David Mankoff , Mark Hibberd , Society Of Nuclear Medicine , Zionexa Us Corp , Ge Healthcare Company , Fred Hutchinson Cancer Center , University Of Pennsylvania , Ge Healthcare , Patient Care Solutions , Ge Healthcare Technologies Inc , Nuclear Medicine , Molecular Imaging , Appropriate Use Criteria , Practice Guidelines , Business Wire , Vice Chair , Breast Medical Oncologist , Chief Medical Officer , Pharmaceutical Diagnostics , Care Technologies , Tumor Characterization , Clinical Trials , Endocrine Therapies ,

GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

(1)
GE Healthcare to scale Zionexa s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen rece ....

United States , David Morris , Kevin Oneill , Hannahm Linden , Olivier Carli , Drug Administration , Zionexa Us Corp , Seattle Cancer Care Alliance In , Ge Healthcare , Molecular Imaging Supply Chain , Medical Affairs , Market Access , Pharmaceutical Diagnostics , Pharmaceutical Diagnostic , Breast Medical Oncologist , Washington Fred Hutchison Cancer Research Center , Seattle Cancer Care Alliance , Prescribing Information , Safety Information , Tumor Characterization , Clinical Trials , Endocrine Therapies , Target Estrogen , Women Living , Metastatic Breast Cancer , Cancer Epidemiology ,

MIL-OSI Economics: GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients

GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18),
used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer
Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023
Acquisition demonstrates GE Healthcare’s commitment to its precision health vision
and builds additional pipeline of oncology and neurology tracers to
help physicians personalize treatment
6 May
2021 – GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for ....

United States , Kevin Oneill , Hannahm Linden , Olivier Carli , Zionexa Us Corp , Drug Administration , Seattle Cancer Care Alliance In , Ge Healthcare , Molecular Imaging Supply Chain , Medical Affairs , Market Access , Pharmaceutical Diagnostics , Pharmaceutical Diagnostic , Breast Medical Oncologist , Washington Fred Hutchison Cancer Research Center , Seattle Cancer Care Alliance , Prescribing Information , Safety Information , Tumor Characterization , Clinical Trials , Endocrine Therapies , Target Estrogen , Estrogen Receptor Expression , Bone Dominant Breast Cancer , Shows Return , ஒன்றுபட்டது மாநிலங்களில் ,